Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
- 25 February 2022
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (5) , 621-631
Abstract
Purpose of Review Adenoid cystic carcinoma (ACC) is a rare and heterogeneous malignancy of secretory glands. Recurrence after curative-intent treatment is common, and approximately 40% of patients develop metastatic disease, for which consensus is lacking regarding therapeutic approaches. Here, we review the available therapies for recurrent/metastatic (R/M) ACC and offer our perspectives on future treatment options. Recent Findings Proteogenomic studies of ACC revealed two molecular subtypes with therapeutic implications: ACC-I (37% of cases) and ACC-II (63%); each has distinct disease biology and prognosis. Molecular drivers, such as NOTCH1, have emerged as potential therapeutic targets for ACC-I and are being explored in clinical trials. Summary Despite its biological heterogeneity, treatment for R/M ACC is not personalized and limited to cytotoxic agents and VEGFR inhibitors, which produce modest responses and significant toxicity. The increasing understanding of ACC’s molecular biology might guide the development of biomarkers for patient selection and new therapies development.Keywords
This publication has 100 references indexed in Scilit:
- Adenoid cystic carcinoma of the head and neckCancer, 2012
- Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinomaBritish Journal of Oral and Maxillofacial Surgery, 2011
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewThe Lancet Oncology, 2011
- MYB Expression and Translocation in Adenoid Cystic Carcinomas and Other Salivary Gland Tumors With Clinicopathologic CorrelationAmerican Journal of Surgical Pathology, 2011
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyJournal of Clinical Oncology, 2010
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neckProceedings of the National Academy of Sciences, 2009
- Recurrent Cancer of the Parotid Gland: How Well Does Salvage Surgery Work for Locoregional Failure?ORL, 2009
- Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II studyOral Oncology, 2009
- Stereotactic Radiosurgery as a Salvage Treatment for Recurrent Skull Base Adenoid Cystic CarcinomaStereotactic and Functional Neurosurgery, 2005
- Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland originHead & Neck, 2002